Alto Neuroscience (NYSE:ANRO) Trading Down 7.3% – What’s Next?

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price fell 7.3% during trading on Thursday . The company traded as low as $31.86 and last traded at $31.5660. Approximately 540,236 shares were traded during mid-day trading, an increase of 41% from the average session volume of 381,970 shares. The stock had previously closed at $34.07.

Analyst Ratings Changes

ANRO has been the topic of a number of recent analyst reports. Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. Wedbush lifted their target price on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. BTIG Research boosted their target price on shares of Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Wolfe Research assumed coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Finally, Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.25.

Alto Neuroscience Price Performance

The firm has a market cap of $1.26 billion, a PE ratio of -13.23 and a beta of 1.13. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The stock has a 50 day simple moving average of $30.68 and a two-hundred day simple moving average of $25.33.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.08. Sell-side analysts expect that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System acquired a new position in Alto Neuroscience in the 2nd quarter valued at approximately $251,000. Wellington Management Group LLP increased its holdings in Alto Neuroscience by 18.6% in the second quarter. Wellington Management Group LLP now owns 70,913 shares of the company’s stock valued at $1,871,000 after purchasing an additional 11,114 shares during the last quarter. AWM Investment Company Inc. bought a new stake in shares of Alto Neuroscience during the second quarter worth $2,111,000. Bank of New York Mellon Corp bought a new position in Alto Neuroscience in the second quarter valued at approximately $2,014,000. Finally, GK Wealth Management LLC bought a new stake in shares of Alto Neuroscience during the 2nd quarter worth about $226,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.